Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Morpholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL2808233 | 1.00 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL28072685 | 1.00 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Sulfuric Acid SCHEMBL8024423 | 0.97 | KDM4E (0.67) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL15789446 | 0.97 | MEN1 (0.58) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL15789448 | 0.97 | MEN1 (0.58) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL15510575 | 0.90 | MEN1 (0.50) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL27791864 | 0.90 | MEN1 (0.50) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL10346420 | 0.89 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL10346421 | 0.89 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL10346419 | 0.89 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055453-B1 | LIGNOCELLULOSIC MATERIALS CONTAINING DEFIBRILLATED CELLULOSE | BASF SE (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-10399246-B2 | Method for producing lignocellulose materials | BASF SE (DE) | 2019-09-03 | — | — | US | disclosed |
| EP-2207416-B1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | IMERYS FILTRATION MINERALS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20180071946-A1 | METHOD FOR PRODUCING LIGNOCELLULOSE MATERIALS | BASF SE (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180071945-A1 | METHOD FOR PRODUCING SINGLE- OR MULTI-LAYER LIGNOCELLULOSE MATERIALS USING TRIALKYL PHOSPHATE | BASF SE (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20170096000-A1 | MULTI-LAYERED LIGNOCELLULOSIC MATERIALS HAVING AN INNERLYING VAPOR BARRIER | BASF SE (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20160257814-A1 | LIGNOCELLULOSIC MATERIALS CONTAINING DEFIBRILLATED CELLULOSE | BASF SE (DE) | 2016-09-08 | — | — | US | disclosed |
| US-20160051112-A1 | FLEXIBLE FLAT SUBSTRATES HAVING AN ABRASIVE SURFACE | BASF SE (DE) | 2016-02-25 | — | — | US | disclosed |
| US-20160046780-A1 | FLEXIBLE FOAMS HAVING AN ABRASIVE SURFACE | BASF SE (DE) | 2016-02-18 | — | — | US | disclosed |
| US-20100239679-A1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | WORLD MINERALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2207416-A1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | World Minerals, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009045941-A1 | ENHANCED RETENTION CAPABILITIES THROUGH METHODS COMPRISING SURFACE TREATMENT OF FUNCTIONAL PARTICULATE CARRIER MATERIALS, AND FUNCTIONAL PARTICULATE CARRIER MATERIALS MADE THEREFROM | WORLD MINERALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-12-07 | — | — | US | disclosed |
| US-4417023-A | POLYOXYETHYLENE-OXYPROPYLENE-SILOXANE COPOLYMER | DIAMOND SHAMROCK CORPORATION (US) | 1983-11-22 | — | — | US | disclosed |
| US-3962150-A | NONIONIC SURFACTANT, ALCOHOL SOLVENT | RICHARDSON-MERRELL INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276339-A1 | Methods and compositions for increasing the efficacy of biologically-active ingredients | ENPP1, ENPP3, SMPD1 | MEN1 1618/4885KMT2A 2581/4885KDM4E 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.